Neoadjuvant bevacizumab, when added to standard chemotherapy for operable breast cancer, improved the rate of complete pathological response in two large, well-conducted trials. However, the modest incremental benefits, combined with uncertain long-term effects on disease recurrence, mean that this approach remains experimental until follow-up data are available.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Department of Health and Human Services. Food and Drug Administration. Docket No. FDA-2010-N-0621. Proposal to withdraw approval for the breast cancer indication for AVASTIN (bevacizumab). Decision of the Commissioner [online], (2011).
Ocaña, A., Amir, E., Vera, F., Eisenhauer, E. A. & Tannock, I. F. Addition of bevacizumab to chemotherapy for treatment of solid tumors: similar results but different conclusions. J. Clin. Oncol. 29, 254–256 (2011).
Bear, H. D. et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N. Engl. J. Med. 366, 310–320 (2012).
von Minckwitz, G. et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N. Engl. J. Med. 366, 299–309 (2012).
von Minckwitz, G. et al. Impact of treatment characteristics on response of difference breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Res. Treat. 125, 145–156 (2011).
Kuerer, H. M. et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J. Clin. Oncol. 17, 460–469 (1999).
Bear, H. D. et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J. Clin. Oncol. 24, 2019–2027 (2006).
Gralow, J. R. et al. Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J. Clin. Oncol. 26, 814–819 (2008).
Chia, S. K. Don't pick the loser: lessons from the GeparQuinto trial. Lancet Oncol. 13, 112–113 (2012).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Burstein, H. Neoadjuvant bevacizumab treatment—signal or noise?. Nat Rev Clin Oncol 9, 191–192 (2012). https://doi.org/10.1038/nrclinonc.2012.34
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2012.34
